2186 Panoramica delle azioni Luye Pharma Group Ltd., una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici in tutto il mondo. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 2186 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Luye Pharma Group Ltd. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Luye Pharma Group Prezzi storici delle azioni Prezzo attuale dell'azione HK$2.16 Massimo di 52 settimane HK$3.77 Minimo di 52 settimane HK$2.20 Beta 0.86 Variazione di 1 mese -17.56% Variazione a 3 mesi -28.48% Variazione di 1 anno -38.29% Variazione a 3 anni -37.39% Variazione a 5 anni -62.50% Variazione dall'IPO -67.76%
Notizie e aggiornamenti recenti Vedi altri aggiornamenti
Luye Pharma Group Ltd. Announces Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland China Dec 03
First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Oct 02
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares Sep 25
Consensus EPS estimates increase by 24%, revenue downgraded Sep 04
First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023) Aug 30
Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet? Aug 29
Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder Jul 29 Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion. Jul 24
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China Jul 04
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors Jun 19
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China Jun 13
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed May 21
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden Apr 26
Now 20% overvalued Apr 24
Now 23% overvalued Apr 08
Full year 2023 earnings: EPS misses analyst expectations Mar 29
Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024 Mar 28
Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 15
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao Mar 09
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 Mar 04
Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount? Feb 29
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States Feb 02
Now 20% undervalued after recent price drop Jan 25
Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S Jan 09
Investor sentiment deteriorates as stock falls 17% Jan 08
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt Dec 19
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong Dec 12
Luye Pharma Group Ltd. Announces Board Changes Dec 06
A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186) Nov 24
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder Oct 11
First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 01
Investor sentiment improves as stock rises 16% Sep 14
Is Luye Pharma Group (HKG:2186) A Risky Investment? Sep 12
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio Sep 09
First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022) Aug 31
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin Aug 22 Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States
Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price Aug 17
Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China Jul 07
Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy Jul 06
Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan Jun 09
Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China Jun 08
Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director May 26
Is Luye Pharma Group (HKG:2186) Using Too Much Debt? May 10
Consensus EPS estimates fall by 11% Apr 15
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 30
Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022) Jan 31
FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder Jan 16
Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010) Dec 29
Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014 Nov 30
Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate Nov 22
Less than half of directors are independent Nov 16
Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA Nov 04 Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding Sep 15
First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021) Aug 31
Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022 Aug 18
Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China Aug 16
Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine Jul 20
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan Jul 19
Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China Jul 15
Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting Jun 09
Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting Jun 07
Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022 May 18
Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China May 12
Full year 2021 earnings: EPS and revenues miss analyst expectations May 02
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 31
Investor sentiment improved over the past week Mar 22
Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection Mar 06
Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China Feb 26
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States Jan 20
Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) Dec 30
Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets Dec 23
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China Dec 15
First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Oct 01
Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in China Sep 29
Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United Kingdom Sep 24
We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt Sep 20
Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia Sep 20
First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020) Sep 01
Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015 Aug 04
Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.S Jun 16
Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in China Jun 11
Investor sentiment improved over the past week May 24
Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in China May 14 Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in China
Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.44 in FY 2019) May 02
Consensus revenue estimates fall to CN¥6.20b Apr 07
Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook Apr 06
Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.46 in FY 2019) Apr 02
Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 Injection Mar 19 Rendimenti per gli azionisti 2186 HK Pharmaceuticals HK Mercato 7D -12.2% -2.1% -0.9% 1Y -38.3% -4.0% 19.2%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 2186 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento -4 % nell'ultimo anno.
Rendimento vs Mercato: 2186 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 19.2 % nell'ultimo anno.
Volatilità dei prezzi Is 2186's price volatile compared to industry and market? 2186 volatility 2186 Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.9% 10% most volatile stocks in HK Market 18.7% 10% least volatile stocks in HK Market 4.1%
Prezzo delle azioni stabile: 2186 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 2186 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1994 5,234 Dian Bo Liu www.luye.cn
Luye Pharma Group Ltd., una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici in tutto il mondo. L'azienda offre Lipusu per il cancro alle ovaie e il carcinoma dell'ovaio; CMNa, un sensibilizzatore chimico per la radioterapia del cancro; Tiandida per il cancro alle ovaie o al polmone non a piccole cellule; Boyounuo, un'iniezione per il trattamento di vari tipi di cancro; e Xuezhikang, un farmaco che regola i lipidi per il trattamento dell'ipercolesterolemia. L'azienda fornisce anche Maitongna per l'edema cerebrale causato da traumi o interventi chirurgici e per i disturbi da reflusso venoso; Beixi, una capsula di acarbosio per il diabete di tipo 2; Apleek Transdermal Patch per la contraccezione; Rivastigmine Transdermal Patch per il trattamento del morbo di Alzheimer; Seroquel e Seroquel XR per il trattamento della schizofrenia e degli episodi maniacali dei disturbi affettivi bipolari.
Mostra di più Luye Pharma Group Ltd. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Luye Pharma Group con la sua capitalizzazione di mercato? 2186 statistiche fondamentali Capitalizzazione di mercato HK$8.35b Guadagni(TTM ) HK$820.38m Ricavi(TTM ) HK$6.72b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 2186 Conto economico (TTM ) Ricavi CN¥6.31b Costo del fatturato CN¥1.97b Profitto lordo CN¥4.34b Altre spese CN¥3.57b Guadagni CN¥770.46m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.20 Margine lordo 68.73% Margine di profitto netto 12.20% Rapporto debito/patrimonio netto 66.6%
Come si è comportato 2186 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/19 14:58 Prezzo dell'azione a fine giornata 2024/12/19 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Luye Pharma Group Ltd. è coperta da 25 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd. Bo Li BOCOM International Securities Limited
Mostra 22 altri analisti 
